Type
|
Public company |
---|---|
Traded as | NASDAQ: DEPO S&P 600 Component |
Industry | Pharmaceutical Industry |
Founded | 1995 (1995) |
Headquarters | Newark, California |
Products | Pharmaceuticals |
Revenue | US$342.7 million (2015) |
Operating income
|
US$-50.4 million (2015) |
Net income
|
US$-75.7 million (2015) |
Total assets | US$1.3 billion (2015) |
Total equity | US$315 million (2015) |
Number of employees
|
494 (December 2015) |
Website | www |
Depomed, Inc. is an American specialty pharmaceutical company which mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. The company is a publicly traded company on NASDAQ under the symbol "DEPO", with several products approved by the United States Food and Drug Administration (FDA).
The company's products include Nucynta ER, Nucynta, Gralise, Cambia, Lazanda, Zipsor, and DM-1992, which mainly focus on pain, neuropathic pain, and central nervous system diseases.
Nucynta ER, Nucynta IR
On January 15, 2015, Depomed announced the acquisition of the Nucynta franchise from Janssen Pharmaceutica for US$1,050,000,000 in cash. The transaction closed on April 2, 2015, and the products are scheduled to be relaunched in June 2015 after a major salesforce expansion.
Gralise
In January 2011, Gralise once-daily (gabapentin extended release) was approved by the US FDA for the treatment of postherpetic neuralgia. The drug has also received Orphan Drug designation from the FDA.
The company's diabetes treatment, Glumetza (metformin hydrochloride extended release tablet), was approved for the treatment of type II diabetes in adults, and is sold in the US by Valeant.
In June 2012, all rights to Zipsor Liquid Filled Capsules was acquired by Depomed from Xanodyne Pharmaceuticals, revenue generated by Zipsor was approximately US$19,000,000 as within the twelve months from Jun 2011 to May 2012.
In March 2012, the company filed a patent infringement lawsuit against three companies that had filed Abbreviated New Drug Applications with the US FDA, claiming infringement of Depomed's six US patents listed for Gralise in the FDA's Orange Book.
2016-07-11 | Reiterated Rating | Royal Bank Of Canada | Hold | |
2016-07-08 | Reiterated Rating | Janney Montgomery Scott | Buy | $28.00 |
2016-06-26 | Reiterated Rating | Mizuho | Buy | |
2016-06-22 | Reiterated Rating | Cantor Fitzgerald | Buy | |
2016-06-15 | Reiterated Rating | Janney Montgomery Scott | Buy | $28.00 |
2016-05-27 | Boost Price Target | Mizuho | Buy | $19.00 to $23.00 |
2016-05-26 | Boost Price Target | Janney Montgomery Scott | Neutral to Hold | $20.13 to $28.00 |
2016-05-17 | Reiterated Rating | Janney Montgomery Scott | Buy | $28.00 |
2016-05-09 | Upgrade | Mizuho | Neutral to Buy | $18.00 to $19.00 |
2016-05-08 | Reiterated Rating | Cantor Fitzgerald | Buy | |
2016-05-06 | Lower Price Target | Piper Jaffray | Overweight | $23.00 to $21.00 |
2016-05-06 | Lower Price Target | Piper Jaffray Cos. | Overweight | $23.00 to $21.00 |
2016-05-02 | Reiterated Rating | RBC Capital | Sector Perform | $22.00 |
2016-05-02 | Reiterated Rating | Royal Bank Of Canada | Sector Perform | $22.00 |
2016-04-26 | Reiterated Rating | Cantor Fitzgerald | Buy | $26.00 |
2016-04-16 | Reiterated Rating | Leerink Swann | Outperform | |
2016-04-12 | Reiterated Rating | Janney Montgomery Scott | Buy | $28.00 |
2016-04-11 | Boost Price Target | Mizuho | Neutral | $14.00 to $18.00 |
2016-04-10 | Reiterated Rating | Cantor Fitzgerald | Buy | $26.00 |
2016-04-09 | Reiterated Rating | Mizuho | Neutral | $14.00 to $18.00 |
2016-03-29 | Reiterated Rating | Cantor Fitzgerald | Buy | $26.00 |
2016-03-29 | Reiterated Rating | Leerink Swann | Outperform | |
2016-03-28 | Reiterated Rating | Roth Capital | Buy | |
2016-03-25 | Lower Price Target | RBC Capital | $24.00 to $22.00 | |
2016-03-24 | Reiterated Rating | Piper Jaffray | Overweight | $23.00 |
2016-03-24 | Initiated Coverage | Northland Securities | Outperform | $22.00 |
2016-03-24 | Lower Price Target | Mizuho | Neutral | $16.00 to $14.00 |
2016-03-10 | Initiated Coverage | Leerink Swann | Outperform | $21.00 |
2016-03-10 | Reiterated Rating | Leerink Partner | Outperform | |
2016-02-25 | Lower Price Target | Mizuho | Buy | $19.00 to $16.00 |
2016-02-24 | Lower Price Target | WallachBeth Capital | Buy | $33.00 to $27.00 |
2016-02-23 | Reiterated Rating | Cantor Fitzgerald | Buy | $27.00 |
2016-02-23 | Reiterated Rating | RBC Capital | Sector Perform | $26.00 to $24.00 |
2016-02-22 | Reiterated Rating | Mizuho | Hold | $19.00 |
2016-02-21 | Reiterated Rating | Piper Jaffray | Overweight | $23.00 |
2016-02-09 | Reiterated Rating | Mizuho | Neutral | $19.00 |
2016-02-08 | Initiated Coverage | Piper Jaffray | Overweight | $23.00 |
2016-02-03 | Reiterated Rating | Cantor Fitzgerald | Buy | $29.00 |
2016-01-20 | Reiterated Rating | Cantor Fitzgerald | Buy | $29.00 |
2016-01-07 | Initiated Coverage | Mizuho | Neutral | $19.00 |
2015-12-04 | Reiterated Rating | Cantor Fitzgerald | Buy | $29.00 |
2015-12-03 | Initiated Coverage | Morgan Stanley | Equal to Equal Weight | $21.00 |
2015-11-30 | Reiterated Rating | Roth Capital | Buy | $24.00 |
2015-11-18 | Reiterated Rating | Janney Montgomery Scott | Buy | |
2015-11-18 | Reiterated Rating | Cantor Fitzgerald | Buy | $29.00 |
2015-11-11 | Boost Price Target | Roth Capital | Buy | $21.00 to $24.00 |
2015-11-11 | Upgrade | WallachBeth Capital | Hold to Buy | $33.00 |
2015-11-10 | Reiterated Rating | Janney Montgomery Scott | Buy | $35.00 |
2015-11-03 | Initiated Coverage | Cantor Fitzgerald | Buy | $29.00 |
2015-10-21 | Lower Price Target | RBC Capital | Sector Perform | $32.00 to $26.00 |
2015-10-20 | Reiterated Rating | Janney Montgomery Scott | Buy | $35.00 |
2015-09-30 | Reiterated Rating | Roth Capital | Buy | $33.00 to $21.00 |
2015-09-01 | Reiterated Rating | Roth Capital | Buy | $33.00 |
2015-07-30 | Downgrade | Janney Montgomery Scott | Buy to Neutral | |
2015-07-30 | Downgrade | RBC Capital | Outperform to Sector Perform | $26.00 to $32.00 |
2015-07-24 | Boost Price Target | WallachBeth Capital | Hold | $26.00 to $33.00 |
2015-07-14 | Boost Price Target | Roth Capital | Buy | $28.50 to $33.00 |
2015-06-11 | Set Price Target | Janney Montgomery Scott | Buy | $25.50 to $26.50 |
2015-06-11 | Initiated Coverage | Morgan Stanley | Equal to Equal Weight | $23.00 |
2015-05-26 | Reiterated Rating | Piper Jaffray | Overweight | $34.00 |
2015-05-12 | Set Price Target | Roth Capital | Buy to Buy | $30.00 to $28.50 |
2015-05-12 | Upgrade | Janney Montgomery Scott | Neutral to Buy | $25.50 |
2015-05-12 | Lower Price Target | RBC Capital | Outperform | $29.00 to $26.00 |
2015-04-22 | Initiated Coverage | Piper Jaffray | Overweight | $37.00 |
2015-04-06 | Boost Price Target | Roth Capital | Buy | $27.00 to $30.00 |
2015-03-19 | Downgrade | Janney Montgomery Scott | Buy to Neutral | $22.00 to $25.50 |
2015-03-13 | Downgrade | WallachBeth Capital | Buy to Hold | $28.00 to $26.00 |
2015-01-16 | Boost Price Target | RBC Capital | Outperform | $20.00 to $22.00 |
2015-01-16 | Upgrade | Roth Capital | Neutral to Buy | $13.50 to $25.00 |
2014-12-10 | Initiated Coverage | RBC Capital | Outperform | $20.00 |
2014-07-10 | Initiated | WallachBeth | Buy | $17 |
2014-07-10 | Initiated Coverage | WallachBeth Capital | Buy | $17.00 |
2014-05-09 | Lower Price Target | Roth Capital | $14.00 to $13.50 | |
2014-04-04 | Boost Price Target | Roth Capital | $12.50 to $14.00 | |
2014-02-13 | Downgrade | Roth Capital | Buy to Neutral | $12.00 to $12.50 |
2013-12-18 | Boost Price Target | JMP Securities | Outperform | $10.00 to $11.00 |
2013-11-22 | Boost Price Target | Roth Capital | $9.00 to $11.00 | |
2013-10-22 | Boost Price Target | JMP Securities | Market Outperform | $9.00 to $10.00 |
2013-02-25 | Downgrade | WallachBeth | Buy to Hold | $8 to $7 |
2012-01-05 | Initiated | JMP Securities | Mkt Outperform | $8 |
2011-09-30 | Initiated | Auriga | Buy | $10 |
2010-02-18 | Downgrade | Merriman | Buy to Neutral | |
2009-10-21 | Initiated | Caris & Company | Buy | $9 |
2009-10-12 | Reiterated | Merriman | Buy | $11.50 to $7.50 |
2009-10-05 | Initiated | Merriman | Buy | |
2008-06-20 | Initiated | Roth Capital | Buy | $5 |
2007-03-15 | Reiterated | Thomas Weisel | Overweight | $8 to $6.50 |
2016-07-11 | Reiterated Rating | Royal Bank Of Canada | Hold | |
2016-07-08 | Reiterated Rating | Janney Montgomery Scott | Buy | $28.00 |
2016-06-26 | Reiterated Rating | Mizuho | Buy | |
2016-06-22 | Reiterated Rating | Cantor Fitzgerald | Buy | |
2016-06-15 | Reiterated Rating | Janney Montgomery Scott | Buy | $28.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In DEPO 16 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
BlackRock Fund Advisors | 6.15M |
BlackRock Institutional Trust Company, N.A. | 1.60M |
RUSSELL FRANK CO/ | 0.32M |
BlackRock Investment Management, LLC | 0.31M |
CORNERSTONE CAPITAL MANAGEMENT HOLDINGS LLC. | 0.19M |
BlackRock Group LTD | 0.13M |
Airain ltd | 0.12M |
MANAGED ACCOUNT ADVISORS LLC | 97070 |
NEW ENGLAND SECURITIES CORP /MA/ | 57950 |
Numeric Investors LLC | 32009 |
BLACKROCK ADVISORS LLC | 31946 |
KCG Holdings, Inc. | 16414 |
CAPSTONE ASSET MANAGEMENT CO | 12580 |
VTL Associates, LLC | 7340 |
MetLife Securities, Inc | 530 |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
STERN JULIAN N | 0.36% (208333) | DEPO / FGEN / |
STAPLE PETER D | 0.20% (117534) | DEPO / |
HIGGINS ARTHUR J President and CEO | 0.19% (111760) | DEPO / ECL / ENDP / ZMH / |
Zenoff David B | 0.16% (93999) | DEPO / EXAM / |
Moretti August J Chief Financial Officer | 0.13% (74447) | ALXA / DEPO / |
BURRILL STEVEN | 0.07% (40000) | DEPO / TRGT / |
Gosling Matthew M VP, General Counsel | 0.03% (19674) | DEPO / |
Srinivas Rao Chief Medical Officer | 0.03% (19527) | DEPO / |
DAWES KAREN A | 0.02% (12867) | DEPO / PDLI / RGEN / |
Sweeney Michael MD VP, Research & Development | 0.02% (9084) | DEPO / |
Saks Samuel R | 0.01% (5099) | ASPX / DEPO / PDLI / TNXP / |
ANIDO VICENTE JR | 0.01% (4403) | AERI / DEPO / |
LAVIGNE LOUIS J JR | 0.01% (4403) | AGN / ARAY / DEPO / ZNGA / |
Shively Richard Scott Chief Commercial Officer | 0.01% (4290) | DEPO / ZGNX / |
Cameron Tammy VP, Finance | 0.01% (3960) | DEPO / |